# EDGAR Filing Document

**Accession Number:** 0001693134
**File Stem:** 0001933414-25-000152
**Filing Date:** 2025-11
**Character Count:** 12650
**Document Hash:** fc9bff6596c4723cec9e2a0162ad4c96
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001933414-25-000152.hdr.sgml**: 20251113

**ACCESSION NUMBER**: 0001933414-25-000152

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251111

**FILED AS OF DATE**: 20251113

**DATE AS OF CHANGE**: 20251113

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Levy Adam Scott
- **CENTRAL INDEX KEY:** 0001693134

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41614
- **FILM NUMBER:** 251480367

**MAIL ADDRESS:**
- **STREET 1:** C/O MIRAGEN THERAPEUTICS, INC.
- **STREET 2:** 6200 LOOKOUT ROAD, #100
- **CITY:** BOULDER
- **STATE:** CO
- **ZIP:** 80301
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Mineralys Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001933414
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 150 N. RADNOR CHESTER ROAD
- **STREET 2:** SUITE F200
- **CITY:** RADNOR
- **STATE:** PA
- **ZIP:** 19087
- **BUSINESS PHONE:** (888) 378-6240

**MAIL ADDRESS:**
- **STREET 1:** 150 N. RADNOR CHESTER ROAD
- **STREET 2:** SUITE F200
- **CITY:** RADNOR
- **STATE:** PA
- **ZIP:** 19087

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Levy Adam Scott<br><sub>(Last) (First) (Middle)</sub><br>150 N. RADNOR CHESTER ROAD,<br>SUITE F200<br><sub>(Street)</sub><br>RADNOR, PA 19087<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-11 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_CFO and Secretary_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Mineralys Therapeutics, Inc. [ MLYS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-11-11 |  | M |  | 20547 | A | $10.20 | 53814<sup>(1)</sup> | D |  |
| Common Stock | 2025-11-11 |  | M |  | 34414 | A | $16 | 88228 | D |  |
| Common Stock | 2025-11-11 |  | M |  | 44079 | A | $14.25 | 132307 | D |  |
| Common Stock | 2025-11-11 |  | M |  | 6613 | A | $15.44 | 138920 | D |  |
| Common Stock | 2025-11-11 |  | S |  | 1015 | D | $42 | 137905 | D |  |
| Common Stock | 2025-11-11 |  | S |  | 11295 | D | 41.8709<sup>(2)</sup> | 126610 | D |  |
| Common Stock | 2025-11-11 |  | S |  | 1561 | D | 42.6794<sup>(3)</sup> | 125049 | D |  |
| Common Stock | 2025-11-11 |  | S |  | 12952 | D | 41.6522<sup>(4)</sup> | 112097 | D |  |
| Common Stock | 2025-11-11 |  | S |  | 8485 | D | 42.3404<sup>(5)</sup> | 103612 | D |  |
| Common Stock | 2025-11-11 |  | S |  | 4142 | D | 43.5015<sup>(6)</sup> | 99470 | D |  |
| Common Stock | 2025-11-11 |  | S |  | 8456 | D | 45.1805<sup>(7)</sup> | 91014 | D |  |
| Common Stock | 2025-11-11 |  | S |  | 38900 | D | 45.9277<sup>(8)</sup> | 52114 | D |  |
| Common Stock | 2025-11-11 |  | S |  | 32718 | D | 46.8848<sup>(9)</sup> | 19396 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option | $10.20 | 2025-11-11 |  | M |  |  | 20547 | <sup>(10)</sup> | 2035-02-13 | Common Stock | 20547 | $0 | 135674<sup>(11)</sup> | D |  |
| Stock Option | $16 | 2025-11-11 |  | M |  |  | 34414 | <sup>(12)</sup> | 2033-02-09 | Common Stock | 34414 | $0 | 20662<sup>(13)</sup> | D |  |
| Stock Option | $14.25 | 2025-11-11 |  | M |  |  | 44079 | <sup>(12)</sup> | 2034-02-13 | Common Stock | 44079 | $0 | 91592<sup>(14)</sup> | D |  |
| Stock Option | $15.44 | 2025-11-11 |  | M |  |  | 6613 | <sup>(12)</sup> | 2033-03-17 | Common Stock | 6613 | $0 | 4888<sup>(15)</sup> | D |  |

---

### Footnotes:

(1) Since the date of the Reporting Person's last ownership report, 83,598 shares of common stock were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.

(2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.4500 to $42.2800. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

(3) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.5100 to $42.9150. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

(4) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.0550 to $42.0400. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

(5) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.1000 to $43.0400. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.

(6) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.1700 to $44.0500. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6) to this Form 4.

(7) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.4700 to $45.4600. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7) to this Form 4.

(8) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.4800 to $46.4725. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (8) to this Form 4.

(9) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.4900 to $47.3600. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (9) to this Form 4.

(10) The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant.

(11) Since the date of the Reporting Person's last ownership report, 13,779 stock options were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.

(12) The stock option vests as to 25% of the total number of shares of common stock subject to the option on the first anniversary of the grant date, and as to 1/48th of  the total number of shares of common stock subject to the option on each monthly anniversary thereafter.

(13) Since the date of the Reporting Person's last ownership report, 42,442 stock options were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.

(14) Since the date of the Reporting Person's last ownership report, 64,329 stock options were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.

(15) Since the date of the Reporting Person's last ownership report, 8,499 stock options were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.

**Signature:** /s/ Adam Levy  
**Date:** 2025-11-13

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**